PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 89 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2022. The put-call ratio across all filers is 1.18 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $1,000 | -98.8% | 252 | -99.1% | 0.00% | – |
| Q1 2022 | $82,000 | -4.7% | 28,399 | 0.0% | 0.00% | – |
| Q4 2021 | $86,000 | -35.3% | 28,399 | +49.1% | 0.00% | – |
| Q3 2021 | $133,000 | -23.6% | 19,041 | +0.4% | 0.00% | – |
| Q2 2021 | $174,000 | -15.1% | 18,959 | -10.0% | 0.00% | – |
| Q1 2021 | $205,000 | -28.3% | 21,074 | -24.5% | 0.00% | – |
| Q4 2020 | $286,000 | +1.4% | 27,900 | 0.0% | 0.00% | – |
| Q3 2020 | $282,000 | -3.1% | 27,900 | 0.0% | 0.00% | – |
| Q2 2020 | $291,000 | +23.8% | 27,900 | 0.0% | 0.00% | – |
| Q1 2020 | $235,000 | +55.6% | 27,900 | +62.2% | 0.00% | – |
| Q4 2019 | $151,000 | -52.8% | 17,200 | -42.1% | 0.00% | – |
| Q3 2019 | $320,000 | -15.1% | 29,700 | 0.0% | 0.00% | – |
| Q2 2019 | $377,000 | -67.3% | 29,700 | 0.0% | 0.00% | -100.0% |
| Q1 2019 | $1,152,000 | +90.7% | 29,700 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $604,000 | -76.1% | 29,700 | -46.1% | 0.00% | -66.7% |
| Q3 2018 | $2,526,000 | -16.2% | 55,092 | +8.2% | 0.00% | -25.0% |
| Q2 2018 | $3,013,000 | +8.5% | 50,932 | +24.8% | 0.00% | +33.3% |
| Q1 2018 | $2,776,000 | -33.5% | 40,798 | -3.4% | 0.00% | -40.0% |
| Q4 2017 | $4,175,000 | -22.2% | 42,237 | -5.7% | 0.01% | -28.6% |
| Q3 2017 | $5,364,000 | +90.3% | 44,792 | +38.9% | 0.01% | +75.0% |
| Q2 2017 | $2,818,000 | +145.9% | 32,247 | +4.7% | 0.00% | +100.0% |
| Q1 2017 | $1,146,000 | +40.3% | 30,801 | +15.8% | 0.00% | +100.0% |
| Q4 2016 | $817,000 | -54.2% | 26,600 | 0.0% | 0.00% | -66.7% |
| Q3 2016 | $1,784,000 | +4.5% | 26,600 | -53.6% | 0.00% | +50.0% |
| Q2 2016 | $1,707,000 | +1.4% | 57,300 | 0.0% | 0.00% | -33.3% |
| Q1 2016 | $1,683,000 | -62.5% | 57,300 | 0.0% | 0.00% | -57.1% |
| Q4 2015 | $4,492,000 | +4.0% | 57,300 | 0.0% | 0.01% | 0.0% |
| Q3 2015 | $4,318,000 | -27.5% | 57,300 | +12.4% | 0.01% | -22.2% |
| Q2 2015 | $5,952,000 | +2216.0% | 50,982 | +4585.8% | 0.01% | – |
| Q1 2015 | $257,000 | -45.8% | 1,088 | -45.2% | 0.00% | -100.0% |
| Q3 2014 | $474,000 | – | 1,985 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HARVARD MANAGEMENT CO INC | 600,000 | $45,216,000 | 3.56% |
| Avalon Global Asset Management LLC | 32,900 | $2,479,000 | 1.79% |
| CORNERSTONE CAPITAL MANAGEMENT LLC | 495,145 | $37,314,000 | 1.58% |
| BB BIOTECH AG | 521,991 | $39,337,000 | 1.25% |
| WEATHERBIE CAPITAL, LLC | 137,041 | $10,327,000 | 1.20% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $428,527,000 | 1.19% |
| TOBAM | 318,384 | $23,994,000 | 0.94% |
| Orbimed Advisors | 1,195,500 | $90,093,000 | 0.91% |
| Capital International Sarl | 109,405 | $8,245,000 | 0.74% |
| CAPITAL INTERNATIONAL LTD /CA/ | 145,697 | $10,980,000 | 0.73% |